EB-2 NIWLife sciences and medicineIndividualDecided May 2023Sustained
Outcome: Sustained
MAY122023_05B5203
Merit and national importanceMetWell positionedMetBalance favors a waiverMet
Our summary
A cancer researcher seeking EB-2 with NIW to continue research in cancer immunotherapy. AAO sustained the appeal, finding the petitioner met all three Dhanasar prongs: the research has substantial merit and national importance; the petitioner is well positioned to advance it; and waiving labor certification benefits the United States given the work's potential to reduce cancer morbidity and mortality.
Official PDF
Official PDF ↗Published by USCIS. The summary is ours, in our own words; the decision text is on uscis.gov.
What the AAO accepted
- Merit and national importance · Cancer immunotherapy research addressing CD8+ T cells and dendritic cells has substantial merit and national importance
- Well positioned · Petitioner demonstrated advanced STEM degree and expertise in cancer immunotherapy research field
- Balance favors a waiver · Proposed work advancing cancer treatments and therapeutic outcomes offers value benefiting United States despite available qualified workers
What was missing
Every criterion in the table was found met.
Criteria
| Criterion | Reading | Why |
|---|---|---|
 Merit and national importance | Met | Cancer immunotherapy research addressing CD8+ T cells and dendritic cells has substantial merit and national importance |
 Well positioned | Met | Petitioner demonstrated advanced STEM degree and expertise in cancer immunotherapy research field |
 Balance favors a waiver | Met | Proposed work advancing cancer treatments and therapeutic outcomes offers value benefiting United States despite available qualified workers |
A published decision describes one case. It is not legal advice and not a prediction for yours.